BioCryst Pharmaceuticals (BCRX) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.31 earnings per share for the quarter, missing the analyst consensus estimate by $-0.08. Analysts had a consensus of $-0.23. The company posted revenue of $4.80 million in the period, compared to analysts expectations of $5.68 million. The company’s revenue was down -29.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.21 EPS.
Many Wall Street Analysts have commented on BioCryst Pharmaceuticals. BioCryst Pharmaceuticals was Downgraded by JP Morgan to ” Neutral” on Feb 9, 2016. BioCryst Pharmaceuticals was Downgraded by Jefferies to ” Hold” on Feb 9, 2016. Shares were Reiterated by FBR Capital on Feb 9, 2016 to “Outperform” and Lowered the Price Target to $ 6 from a previous price target of $18 .
BioCryst Pharmaceuticals closed down -0.24 points or -7.41% at $3 with 10,14,813 shares getting traded on Wednesday. Post opening the session at $3.2, the shares hit an intraday low of $2.97 and an intraday high of $3.29 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Dec 22, 2015, Thomas R Ii Staab (Senior Vice President and CFO) sold 3,052 shares at $10.86 per share price. According to the SEC, on Jun 22, 2015, William P Sheridan (Senior VP – CMO) sold 70,389 shares at $15.05 per share price. On Jun 22, 2015, Alane P Barnes (VP, General Counsel & Corp Sec) sold 3,000 shares at $15.00 per share price, according to the Form-4 filing with the securities and exchange commission.
BioCryst Pharmaceuticals Inc. (BioCryst) is a biotechnology company. The Company designs optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB BCX4161 BCX7353 and other second generation HAE compounds BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza in the United States as RAPIVAB in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.